Benefits of Metformin (Longevity Context)

Evidence-Based Benefits

• Longevity association — Bannister et al. (2014) analyzed UK Clinical Practice Research Datalink data and found that type 2 diabetics on metformin had 15% lower all-cause mortality than matched non-diabetic controls, suggesting benefits beyond glucose control
• AMPK activation and mTOR inhibition — metformin activates AMP-activated protein kinase and inhibits mTOR complex 1, engaging two of the most critical longevity pathways that also mediate caloric restriction's benefits
• Cancer risk reduction — multiple observational studies and meta-analyses show metformin users have 30-40% lower incidence of several cancers including breast, colorectal, and pancreatic cancer (Gandini et al., 2014)
• Anti-inflammatory — metformin reduces CRP, TNF-α, and IL-6, and inhibits NF-κB signaling, addressing the chronic low-grade inflammation ("inflammaging") that drives age-related disease
• Cardiovascular protection — the UKPDS trial demonstrated metformin reduced cardiovascular events by 39% in overweight type 2 diabetes patients independently of glucose control

What the Research Says

Metformin's longevity potential is supported by strong observational data but lacks definitive interventional proof in non-diabetics. Bannister et al. (2014) published the landmark observational finding of 15% mortality reduction. The TAME trial (Targeting Aging with Metformin), led by Nir Barzilai, is the first FDA-approved trial specifically testing an anti-aging drug in humans — it will track composite age-related outcomes in ~3,000 participants aged 65-79. Gandini et al. (2014) meta-analyzed the cancer risk reduction data. The key controversy is Konopka et al. (2019), who showed metformin blunted exercise-induced mitochondrial improvements — raising questions about whether metformin's AMPK activation might compete with exercise's AMPK activation. This is a prescription medication and should only be used under medical supervision.

Related Conditions